

Lupin appoints Theresa Stevens as chief corporate development officer

22 April 2014 | News | By BioSpectrum Bureau

Lupin appoints Theresa Stevens as chief corporate development officer



Pharma major Lupin announced the appointment of Theresa Stevens as Chief Corporate Development Officer for its global operations. Ms Stevens will assume full responsibility for global merger and acquisitions and specialty business strategy. Prior to joining Lupin, she was with Aptalis pharma as the chief corporate development officer responsible for Mergers and Acquisitions (M&A), Strategy and Global Business Development. Before Aptalis, Ms Stevens was in Novartis for 9+ years and held positions of increasing responsibility including head, Global BD&L for General Medicines, executive director and head, Global BD&L for Respiratory and Dermatology Business Units and head US Business Development and Licensing, life cycle management and generic brand strategies.

Ms Stevens has a Masters Degree in Biochemistry from University of Maryland and is a Juris Doctor (J.D) from the Widener University School of Law, Wilmington, Delaware. She started her career as a research scientist at Dupont and has practiced Corporate Law at Pennie and Edmonds (Jones Day). Having worked with Aptalis and Novartis, Ms Stevens has over 27 years of experience in the Pharmaceutical and Biotech sector with significant experience in managing strategy, corporate development, M&A and licensing.

Commenting on the appointment, Nilesh Gupta, managing director, Lupin Limited said, "I am very pleased to welcome Theresa to the Lupin family. I am sure her rich experience in the areas of M&A and Specialty Strategy within the pharmaceutical and biotech industry sector will help Lupin's growth plans."